Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13804946 | 0.98 | TSHR (0.42) | TSHRHRH3CYP4F2CYP4A11MEN1 | |
| SCHEMBL14898427 | 0.95 | CYP4F2 (0.42) | TSHRHRH3CYP4F2CYP4A11MEN1 | |
| SCHEMBL21344909 | 0.88 | MEN1 (0.45) | TSHRHRH3CYP4F2CYP4A11MEN1 | |
| SCHEMBL12561571 | 0.88 | TSHR (0.42) | TSHRHRH3CYP4F2CYP4A11MEN1 | |
| SCHEMBL14190949 | 0.88 | TSHR (0.54) | TSHRHRH3CYP4F2CYP4A11MEN1 | |
| SCHEMBL16419397 | 0.86 | MEN1 (0.52) | TSHRHRH3CYP4F2CYP4A11MEN1 | |
| SCHEMBL7182245 | 0.84 | HRH3 (0.47) | TSHRHRH3 | |
| SCHEMBL6255271 | 0.82 | HRH3 (0.38) | TSHRHRH3MEN1KMT2ATHRB | |
| SCHEMBL25960823 | 0.82 | HRH3 (0.46) | TSHRHRH3MEN1KMT2ATHRB | |
| SCHEMBL19668069 | 0.81 | TSHR (0.52) | TSHRHRH3CYP4F2CYP4A11MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160039879-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. (US) | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039879-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | FKBP1B, MALT1, FKBP5 | TSHR 4131/4885HRH3 4805/4885CYP4F2 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.